Literature DB >> 21864184

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Vanja Vaccaro, Isabella Sperduti, Michele Milella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21864184     DOI： 10.1056/NEJMc1107627

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  67 in total

1.  Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study.

Authors:  Michael Blaszak; Maher El-Masri; Khalid Hirmiz; John Mathews; Abeer Omar; Tarek Elfiki; Rasna Gupta; Caroline Hamm; Sindu Kanjeekal; Amin Kay; Swati Kulkarni; Akmal Ghafoor
Journal:  Mol Clin Oncol       Date:  2017-03-01

Review 2.  Genomic alterations in pancreatic cancer and their relevance to therapy.

Authors:  Erina Takai; Shinichi Yachida
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

3.  GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Authors:  R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca
Journal:  Oncogene       Date:  2018-07-30       Impact factor: 9.867

4.  EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.

Authors:  Michael J Levy; Steven R Alberts; William R Bamlet; Patrick A Burch; Michael B Farnell; Ferga C Gleeson; Michael G Haddock; Michael L Kendrick; Ann L Oberg; Gloria M Petersen; Naoki Takahashi; Suresh T Chari
Journal:  Gastrointest Endosc       Date:  2016-11-23       Impact factor: 9.427

5.  Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.

Authors:  Pauline Macaire; Justine Paris; Julie Vincent; François Ghiringhelli; Leïla Bengrine-Lefevre; Antonin Schmitt
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

Review 6.  Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Authors:  Vanja Vaccaro; Isabella Sperduti; Sabrina Vari; Emilio Bria; Davide Melisi; Carlo Garufi; Carmen Nuzzo; Aldo Scarpa; Giampaolo Tortora; Francesco Cognetti; Michele Reni; Michele Milella
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 7.  CNS involvement in pancreatic adenocarcinoma: a report of eight cases from the Johns Hopkins Hospital and review of literature.

Authors:  Abhijeet Kumar; Meenakshi Dagar; Joseph Herman; Christine Iacobuzio-Donahue; Dan Laheru
Journal:  J Gastrointest Cancer       Date:  2015-03

8.  Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Authors:  Maeve A Lowery; Winston Wong; Emmet J Jordan; Jonathan W Lee; Yelena Kemel; Joseph Vijai; Diana Mandelker; Ahmet Zehir; Marinela Capanu; Erin Salo-Mullen; Angela G Arnold; Kenneth H Yu; Anna M Varghese; David P Kelsen; Robin Brenner; Erica Kaufmann; Vignesh Ravichandran; Semanti Mukherjee; Michael F Berger; David M Hyman; David S Klimstra; Ghassan K Abou-Alfa; Catherine Tjan; Christina Covington; Hannah Maynard; Peter J Allen; Gokce Askan; Steven D Leach; Christine A Iacobuzio-Donahue; Mark E Robson; Kenneth Offit; Zsofia K Stadler; Eileen M O'Reilly
Journal:  J Natl Cancer Inst       Date:  2018-10-01       Impact factor: 13.506

Review 9.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

10.  Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?

Authors:  Meng Li; Miao-Miao Wang; Xiu-Wei Guo; Chao-Yong Wu; Dao-Rui Li; Xing Zhang; Pei-Tong Zhang
Journal:  Chin J Integr Med       Date:  2017-10-24       Impact factor: 1.978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.